R_3 is H, C $_{1-6}$ alkyl, phenyl, or benzyl;

each of R_5, R_6, R_7 and R_8 is independently H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, or amino, with the proviso that R_7 is methyl;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, and amino;

W is ~~R_9-O-R_9, NR_{10}, -(CO)(O)R_9, -N(R_{10})SO_2-R_9, -O-(CO)R_9, -(CO)NR_{10}, or -N(R_{10})-CO-R_9,~~ wherein R_9 is C $_{1-6}$ alkylene, C $_{2-6}$ alkynylene, C $_{2-6}$ alkenylene, phenylene, or C $_{2-5}$ heterocyclic bivalent radical~~, and R_{10} is H, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, phenyl, or C $_{2-5}$ heterocyclic radical~~;

Y is absent, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, or C $_{1-6}$ alkoxy;

Z is C $_{2-8}$ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2, wherein G is R_{15}, COR_{15}, $COOR_{15}$, SO_2R_{15}, SO_2N or CSR_{15}; ~~or Z is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C $_{1-6}$ alkyl, phenyl, benzyl, C $_{3-8}$ cycloalkyl, and C $_{2-5}$ heterocyclic radical;~~ and R_{15} is C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, C $_{3-7}$ cycloalkyl, or C $_{4-7}$ cycloalkenyl;

~~provided that where R_c is $WNR_{11}R_{12}$, each of R_{11} and R_{12} being independently selected from C $_{1-6}$ alkyl, then at least one of the following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is -R_9-, -NR_{10}-, -(CO)(O)R_9-, -O-(CO)R_9-, -(CO)NHR_9-, or -N(R_{10})(CO)R_9-;~~

~~and further provided that where each of R_a, R_b, R_d, and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent one carbon-carbon double bond or are absent; or R_7 or R_8 is alkyl, alkoxy, halo, or amino;~~

~~and further provided that where each of R_a, R_b, R_d, and R_e is H, and W is a straight chain, unsubstituted propoxy, then YZ is not N-piperidyl or N-morpholinyl;~~ and

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, C_{2-5} heterocyclic radical, phenyl, and phenyl(C_{1-3} alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;

or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

2. (currently amended) A compound of claim 1, wherein Z comprises piperidyl, morpholinyl, ~~benzyl amino, phenyl amino, substituted benzyl amino,~~ piperazinyl, pyrrolidyl, or a C_{6-8} cycloalkylimino radical.

3. (deleted)

~~4.~~ (original) A compound of claim 1, wherein W is hydroxy-substituted C_{2-4} alkoxy, or C_{2-4} alkoxy, ~~C_{2-4} alkylamino, butenyl, or butynyl~~.

~~5.~~ (currently amended) A compound of claim 1, wherein W comprises propoxy, or ethoxy, ~~propylamino, or ethylamino; and one of R_7 and R_8 is methyl~~.

6. (deleted)

~~7.~~ (original) A compound of claim 1 wherein at least one of R_a, R_b, R_d, and R_e is methyl.

~~8.~~ (currently amended) A compound of claim 1, wherein each of R_5, R_6, ~~R_7~~ and R_8 is independently H, methyl, ethyl, methoxy, ethoxy, fluoro, or chloro; or wherein one of R_a, R_b, R_c, R_d, and R_e is WZ

and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, fluoro, or chloro; or both.

~~9.~~ (original) A compound of claim 1, wherein both dashed lines are present to form two carbon-carbon double bonds.

~~10.~~ (original) A compound of claim 1, wherein both dashed lines are absent.

~~11.~~ (original) A compound of claim 1, wherein R_a or R_e is methyl, fluoro, or methoxy.

~~12.~~ (original) A compound of claim 1, provided that where each of R_a, R_b, R_d, and R_e is H, and W is a straight chain, unsubstituted alkoxy; then at least ~~two~~ one of the following are is true: ~~Z is cyclic;~~ at least one of the dashed lines is absent; and R_7 or R_8 is methyl.

13. (deleted)

~~14.~~ (currently amended) A compound of claim 1, wherein

R_3 is H or methyl;

each of R_b and R_d is independently H, methyl, or methoxy;

~~each of R_7 and R_8~~ is ~~independently~~ H, methyl, fluoro, or chloro;

each of R_5 and R_6 is H;

each of R_a or R_e is independently H, methyl, fluoro, or chloro;

W is C_{2-4} alkoxy~~, C_4 alkylene, C_4 alkynylene, C_4 alkenylene, $N(R_{10})SO_2$-(C_{1-5} alkyl), -(CO)O-C_{2-3} alkyl, -(CO)NH-(C_{1-3} alkyl), -NH(CO)(C_{1-3} alkyl), or -NH(C_{1-6} alkyl)~~; and

Z is pyrrolidyl, piperidyl, morpholinyl, piperazinyl, (piperidyl)-piperidyl~~, or $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-5} alkyl, phenyl, benzyl, C_{3-8} cycloalkyl, and C_{2-5} heterocyclic radical, but at least one of R_{11} and R_{12} is not H; or taken together, R_{11} and R_{12} with the N to which they are attached form a C_{6-8} cycloalkylimino radical~~.

15. (deleted)

12 ~~16.~~ (currently amended) A compound of claim 2, selected from 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-~~Cycloheptylamino~~hexamethyleneimino propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; ~~2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine;and 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine~~;~~ ~~2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; and 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine~~.

13 ~~17.~~ (currently amended) A compound ~~of claim 2,~~ selected from ~~N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;~~ 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; and 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine~~; and N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine~~.

14 ~~18.~~ (original) A compound of claim ~~16,~~ 12 having the formula 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

15 ~~19.~~ (currently amended) A pharmaceutical composition comprising a compound of ~~formula~~ claim 1 ~~(I)~~ and a pharmaceutically-acceptable carrier.

16 ~~20.~~ (currently amended) A pharmaceutical composition of claim ~~19,~~ 15 wherein said compound has a formula wherein R_3 is H or methyl; each of R_b and R_d is independently H, methyl, or methoxy; ~~each of R_7 and R_8~~ is ~~independently~~ H, methyl, fluoro,

or chloro; each of R_5 and R_6 is H; each of R_a or R_e is independently H, methyl, fluoro, or chloro; W is C_{2-4} alkoxy~~, C_4 alkylene, C_4 alkynylene, C_4 alkenylene, -(CO)O-C_{2-3} alkyl, -N(R_{10})SO_2-R_9, -(CO)NH-(C_{1-3} alkyl), -NH(CO)(C_{1-3} alkyl), or NH(C_{1-6} alkyl)~~; and Z is pyrrolidyl, piperidyl, morpholinyl, piperazinyl, (piperidyl)-piperidyl~~, or $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-5} alkyl, phenyl, benzyl, C_{3-8} cycloalkyl, and C_{2-5} heterocyclic radical, but at least one of R_{11} and R_{12} is not H; or taken together, R_{11} and R_{12} with the N to which they are attached form a C_{6-8} cycloalkylimino radical~~.

A 2 cont

17 ~~21~~. (currently amended) A pharmaceutical composition of claim 16 ~~20~~, wherein said compound has a formula selected from ~~2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;~~ 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-~~Cycloheptylamino~~ hexamethyleneimino propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; ~~2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; and ~~2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-~~

B

~~5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine;~~ 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine;~~and N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine~~.

~~22.~~ (original) A pharmaceutical composition of claim ~~20~~, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

~~23.~~ (currently amended) A method for treating disorders mediated by the histamine H_3 receptor in a patient, said method comprising administering to the patient a pharmaceutically effective amount of compound of formula (I):



wherein ~~both~~ dashed lines ~~are~~ a carbon-carbon double bond, or ~~both are~~ absent;

R_3 is H, C $_{1-6}$ alkyl, phenyl, or benzyl;

each of R_5, R_6, R_7 and R_8 is independently H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, or amino;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, and amino;

W is ~~R_9-~~O-R_9, ~~NR_{10}-, -(CO)(O)R_9-, -N(R_{10})SO_2-R_9-, -O-(CO)R_9-, -(CO)NR_{10}-, or -N(R_{10})-CO-R_9-~~ wherein R_9 is C $_{1-6}$ alkylene, C $_{2-6}$ alkynylene, C $_{2-6}$ alkenylene, phenylene, or C $_{2-5}$ heterocyclic bivalent radical~~, and R_{10} is H, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, phenyl, or C $_{2-5}$ heterocyclic radical~~;

Y is absent, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, or C $_{1-6}$ alkoxy;
Z is C $_{2-8}$ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2, wherein G is R_{15}, COR_{15}, $COOR_{15}$, SO_2R_{15}, SO_2N or CSR_{15}; ~~or Z is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C $_{1-6}$ alkyl, phenyl, benzyl, C $_{3-8}$ cycloalkyl, and C $_{2-5}$ heterocyclic radical;~~ and R_{15} is C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, C $_{3-7}$ cycloalkyl, or C $_{4-7}$ cycloalkenyl;

~~provided that where R_6 is $WNR_{11}R_{12}$, each of R_{11} and R_{12} being independently selected from C $_{1-6}$ alkyl, then at least one of the following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is $-R_9-$, $-NR_{10}-$, $-(CO)(O)R_9-$, $-O(CO)R_9-$, $-(CO)NHR_9-$, or $-N(R_{10})(CO)R_9-$;~~

~~and further provided that where each of R_a, R_b, R_d, and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent one carbon-carbon double bond or are absent; or R_7 or R_8 is alkyl, alkoxy, halo, or amino;~~ and

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C $_{1-3}$ alkyl, halo, hydroxy, C $_{2-5}$ heterocyclic radical, phenyl, and phenyl(C $_{1-3}$ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;

or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

~~24.~~ (currently amended) A method of claim ~~23,~~ wherein said compound is selected from ~~2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine;~~

~~(E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;~~ 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-~~Cycloheptylamino~~hexamethylene imino propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; ~~2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; ~~2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;~~ 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine;~~ 2-(4-piperidino-propoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

~~25.~~ (original) A method of claim ~~23~~ 19, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

~~26~~. (currently amended) A method for treating a patient with a central nervous system disorder, said method comprising administering to the patient a pharmaceutically-effective amount of a compound of formula (I):

T1960



B A2 B cont

B2

independently each completes

wherein ~~both~~ dashed lines ~~are~~ is a carbon-carbon double bond, or ~~both are~~ absent;

R_3 is H, C_{1-6} alkyl, phenyl, or benzyl;

each of R_5, R_6, R_7 and R_8 is independently H, C_{1-6} alkyl, C_{1-6} alkoxy, halo, or amino;

B2

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C_{1-6} alkyl, C_{1-6} alkoxy, halo, and amino;

W is O-R_9, wherein R_9 is C_{1-6} alkylene, C_{2-6} alkynylene, C_{2-6} alkenylene, phenylene, or C_{2-5} heterocyclic bivalent radical, and R_{10} is H, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, phenyl, or C_{2-5} heterocyclic radical;

Y is absent, C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, or C_{1-6} alkoxy;

Z is C_{2-8} heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2, wherein G is R_{15}, COR_{15}, $COOR_{15}$, SO_2R_{15}, SO_2N or CSR_{15}; and R_{15} is C_{1-6} alkyl, C_{2-6} alkynyl, C_{2-6} alkenyl, C_{3-7} cycloalkyl, or C_{4-7} cycloalkenyl;

and

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, C_{2-5} heterocyclic radical, phenyl, and phenyl(C_{1-3} alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;

A

or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

27. (deleted)

28. (original) A method of claim ~~26~~ 22, wherein said central nervous system disorder is selected from sleep/wake disorders, arousal/vigilance disorders, dementia, Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorder, learning and memory disorders, mild cognitive impairment, and schizophrenia.

29. (original) A method of claim ~~26~~ 22, wherein said central nervous system disorder is selected from Alzheimer's disease, epilepsy, eating disorders, learning and memory disorders, migraine, sleep/wake disorders, allergic rhinitis, schizophrenia, mild cognitive impairment, and asthma.

30. (currently amended) A method of claim ~~26~~ 22, wherein said compound is selected from ~~2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;~~ 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-~~Cycloheptylamino~~hexamethyleneimino propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; ~~2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-

methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; ~~2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;~~ 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine;~~ 2-(4-piperidino-propoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

~~31~~. (original) A method of claim ~~27~~, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

~~32~~. (original) A method of claim ~~26~~, wherein said disorder is selected from sleep/wake disorders, arousal/vigilance disorders, attention deficit hyperactivity disorder, and learning and memory disorders.

~~33~~. (currently amended) A method for treating a patient with an upper airway allergic response, said method comprising administering to the patient a pharmaceutically-effective amount of a compound of formula (I):



wherein ~~both~~ dashed lines ~~are~~ a carbon-carbon double bond, or ~~both are~~ absent;

R_3 is H, C $_{1-6}$ alkyl, phenyl, or benzyl;

each of R_5, R_6, R_7 and R_8 is independently H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, or amino;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C $_{1-6}$ alkyl, C $_{1-6}$ alkoxy, halo, and amino;

W is ~~R_9, O-R_9, NR_{10}, -(CO)(O)R_9, -N(R_{10})SO_2-R_9-, -O-(CO)R_9, -(CO)NR_{10}, or -N(R_{10})-CO-R_9,~~ wherein R_9 is C $_{1-6}$ alkylene, C $_{2-6}$ alkynylene, C $_{2-6}$ alkenylene, phenylene, or C $_{2-5}$ heterocyclic bivalent radical, and R_{10} is H, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, phenyl, or C $_{2-5}$ heterocyclic radical;

Y is absent, C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, or C $_{1-6}$ alkoxy;

Z is C $_{2-8}$ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO_2, wherein G is R_{15}, COR_{15}, $COOR_{15}$, SO_2R_{15}, SO_2N or CSR_{15}; ~~or Z is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C $_{1-6}$ alkyl, phenyl, benzyl, C $_{3-8}$ cycloalkyl, and C $_{2-5}$ heterocyclic radical;~~ and R_{15} is C $_{1-6}$ alkyl, C $_{2-6}$ alkynyl, C $_{2-6}$ alkenyl, C $_{3-7}$ cycloalkyl, or C $_{4-7}$ cycloalkenyl;

~~provided that where R_c is $WNR_{11}R_{12}$, each of R_{11} and R_{12} being independently selected from C $_{1-6}$ alkyl, then at least one of the following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is -R_9-, -NR_{10}-, -(CO)(O)R_9-, -O-(CO)R_9-, -(CO)NHR_9-, or -N(R_{10})(CO)R_9-;~~

~~and further provided that where each of R_a, R_b, R_d, and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent~~

~~one carbon-carbon double bond or are absent; or R_7 or R_8 is alkyl, alkoxy, halo, or amino;~~ and

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C $_{1-3}$ alkyl, halo, hydroxy, C $_{2-5}$ heterocyclic radical, phenyl, and phenyl(C $_{1-3}$ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;

or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

A-1 Cont

29 ~~34~~. (currently amended) A method of claim ~~33~~ 28, wherein said compound is selected from ~~2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;~~ 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-~~Cycloheptylamino~~hexamethyleneimino propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; ~~2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; ~~2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine;~~ 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine;~~ 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-

B

4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; ~~N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine;~~ 2-(4-piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

~~35~~ 30. (original) A method of claim ~~33~~ 28, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.